- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.05. | Medical remote monitoring: a revolution driven by connected patches | ||
| 30.04. | Eli Lilly and Creyon Bio enter oligonucleotide therapy partnership worth over $1bn | ||
| 30.04. | AbbVie's JAK inhibitor Rinvoq granted FDA approval to treat giant cell arteritis | ||
| 30.04. | AstraZeneca's Calquence regimens recommended by CHMP for chronic lymphocytic leukaemia | ||
| 30.04. | Mastering pharma capability development cogs | ||
| 29.04. | Regeneron's bispecific antibody Lynozyfic approved by EC to treat multiple myeloma | ||
| 29.04. | MHRA approves Autolus Therapeutics' Aucatzyl to treat acute lymphoblastic leukaemia | ||
| 29.04. | Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma | ||
| 29.04. | Client/agency partnerships - a marriage of science and creativity | ||
| 28.04. | Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition | ||
| 28.04. | Roche to boost US footprint with $50bn investment over next five years | ||
| 28.04. | Pfizer's sasanlimab improves event-free survival in phase 3 bladder cancer trial | ||
| 28.04. | Health misinformation: can pharma really have an impact? | ||
| 25.04. | Johnson & Johnson's Tremfya granted EC approval to treat ulcerative colitis in adults | ||
| 25.04. | Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m | ||
| 25.04. | Ipsen's elafibranor shows promise in rare liver disease primary sclerosing cholangitis | ||
| 25.04. | The AI revolution in healthcare - unlocking a new era of medical innovation | ||
| 24.04. | Roche's Genentech enters $765m autoimmune disease partnership with Repertoire | ||
| 24.04. | Biogen's Skyclarys granted MHRA approval for rare movement disorder Friedreich's ataxia | ||
| 24.04. | Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer | ||
| 24.04. | DE&I - don't throw the baby out with the bathwater | ||
| 23.04. | Pfizer's Hympavzi granted MHRA approval to treat haemophilia A and B | ||
| 23.04. | BMS receives NICE recommendation for immunotherapy combination in colorectal cancer | ||
| 23.04. | AstraZeneca/Daiichi Sankyo's Enhertu shows promise in first-line HER2-positive breast cancer | ||
| 23.04. | Tackling the antibiotic resistance crisis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .